|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2020-04-28 |
A Prospective, Observational Study of Bafiertam Evaluating Persistence on Treatment, Safety, Tolerability, And Effectiveness In Routine Clinical Practice.
This is an open-label, multicenter, observational study of the adherence of patients with relapsing-remitting multiple sclerosis (RRMS) prescribed Bafiertam (monomethyl fumarate) as their treatment.
An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)
This is an open-label, multicenter, observational study evaluating GI symptoms in relapsing-remitting multiple sclerosis (RRMS) patients who switch from dimethyl fumarate (DMF) to Bafiertam®.
A Single-Dose, Randomized, Open-Label, Two-Way Crossover, Bioequivalence Study of Bafiertam (Monomethyl Fumarate) 190 mg and Vumerity® (Diroximel Fumarate) 462 mg Delayed-Release Capsules in Fasting Healthy Male and Female Subjects
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
100 项与 Banner Life Sciences LLC 相关的临床结果
0 项与 Banner Life Sciences LLC 相关的专利(医药)
100 项与 Banner Life Sciences LLC 相关的药物交易
100 项与 Banner Life Sciences LLC 相关的转化医学